Lipidomics of essential fatty acids and oxygenated metabolites

Molecular Nutrition and Food Research

Volumn 57, Issue 8, 2013, Pages 1347-1358

  Lagarde, Michel ^a   Bernoud Hubac, Nathalie ^a   Calzada, Catherine ^a   Véricel, Evelyne ^a   Guichardant, Michel ^a  

^a UNIVERSITÉ DE LYON   (France)

Author keywords

Fluxes; Leukotrienes; Metabolism; Peroxidation; Prostanoids

Indexed keywords

ARACHIDONIC ACID; ENDOCANNABINOID; ESSENTIAL FATTY ACID; LEUKOTRIENE; LINOLEIC ACID; LINOLENIC ACID; OXYGEN; UNSATURATED FATTY ACID;

BIOAVAILABILITY; FLUXES; HUMAN; LIPID PEROXIDATION; METABOLISM; PEROXIDATION; PROSTANOIDS; REVIEW;

FLUXES; LEUKOTRIENES; METABOLISM; PEROXIDATION; PROSTANOIDS;

ALPHA-LINOLENIC ACID; ARACHIDONIC ACID; BIOLOGICAL AVAILABILITY; ENDOCANNABINOIDS; FATTY ACIDS, ESSENTIAL; FATTY ACIDS, UNSATURATED; HUMANS; LINOLEIC ACID; LIPID PEROXIDATION; OXYGEN;

EID: 84881274650     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201200828     Document Type: Review

References (115)

1. Burdge, G. C., Metabolism of alpha-linolenic acid in humans. Prostaglandins Leukot. Essent. Fatty Acids 2006, 75, 161-168.
2. Siguel, E. N., Chee, K. M., Gong, J. X., Schaefer, E. J., Criteria for essential fatty acid deficiency in plasma as assessed by capillary column gas-liquid chromatography. Clin. Chem. 1987, 33, 1869-1873.
3. Kurvinen, J. P., Kuksis, A., Sinclair, A. J., Abedin, L., Kallio, H., The effect of low alpha-linolenic acid diet on glycerophospholipid molecular species in guinea pig brain. Lipids 2000, 35, 1001-1009.
4. Rosenthal, M. D., Garcia, M. C., Jones, M. R., Sprecher, H., Retroconversion and delta 4 desaturation of docosatetraenoate (22:4(n-6)) and docosapentaenoate (22:5(n-3)) by human cells in culture. Biochim. Biophys. Acta 1991, 1083, 29-36.
5. Furland, N. E., Maldonado, E. N., Aveldaño, M. I., Very long chain PUFA in murine testicular triglycerides and cholesterol esters. Lipids 2003, 38, 73-80.
6. Berdeaux, O., Juaneda, P., Martine, L., Cabaret, S. et al., Identification and quantification of phosphatidylcholines containing very-long-chain polyunsaturated fatty acid in bovine and human retina using liquid chromatography/tandem mass spectrometry. J. Chromatogr. A. 2010, 1217, 7738-7748.
7. McLean, L. R., Best, S., Balasubramaniam, A., Jackson, R. L., Fatty acyl chain specificity of phosphatidylcholine hydrolysis catalyzed by lipoprotein lipase. Effect of apolipoprotein C-II and its (56-79) synthetic fragment. Biochim. Biophys. Acta 1986, 878, 446-449.
8. Mayer, R. J., Marshall, L. A., New insights on mammalian phospholipase A2(s); comparison of arachidonoyl-selective and -nonselective enzymes. FASEB J. 1993, 7, 339-348.
9. Authi, K. S, Lagarde, M., Crawford, N., Diacylglycerol lipase activity in human platelet intracellular and surface membranes. Some kinetic properties and fatty acid specificity. FEBS Lett. 1985, 180, 95-101.
10. Brindley, D. N., Waggoner, D. W., Phosphatidate phosphohydrolase and signal transduction. Chem. Phys. Lipids 1996, 80, 45-57.
11. Farooqui, A. A., Horrocks, L. A., Farooqui, T., Deacylation and reacylation of neural membrane glycerophospholipids. J. Mol. Neurosci. 2000, 14, 123-135.
12. Portilla, D., Shah, S. V., Lehman, P. A., Creer, M. H., Role of cytosolic calcium-independent plasmalogen-selective phospholipase A2 in hypoxic injury to rabbit proximal tubules. J. Clin. Invest. 1994, 93, 1609-1615.
13. Prescott, S. M., Zimmerman, G. A., Stafforini, D. M., McIntyre, T. M., Platelet-activating factor and related lipid mediators. Annu. Rev. Biochem. 2000, 69, 419-445.
14. Bussolino, F., Camussi, G., Platelet-activating factor produced by endothelial cells. A molecule with autocrine and paracrine properties. Eur. J. Biochem. 1995, 229, 327-337.
15. Hamberg, M., Samuelsson, B., Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets. Proc. Natl. Acad. Sci. USA 1974, 71, 3400-3404.
16. Samuelsson, B., Folco, G., Granström, E., Kindahl, H., Malmsten, C., Prostaglandins and thromboxanes: biochemical and physiological considerations. Adv. Prostagland. Thrombox. Res. 1978, 4, 1-25.
17. Moncada, S., Vane, J. R., Prostacyclin in the cardiovascular system. Adv. Prostagland. Thrombox. Res. 1980, 6, 43-60.
18. Hirabayashi, T., Shimizu, T., Localization and regulation of cytosolic phospholipase A(2). Biochim. Biophys. Acta 2000, 1488, 124-138.
19. Glatz, J. F., Börchers, T., Spener, F., van der Vusse, G. J., Fatty acids in cell signalling: modulation by lipid binding proteins. Prostaglandins Leukot. Essent. Fatty Acids 1995, 52, 121-127.
20. Hornych, A., Safar, M., Papanicolaou, N., Meyer, P., Milliez, P., Renal and cardiovascular effect of prostaglandin A2 in hypertensive patients. Eur. J. Clin. Invest. 1973, 3, 391-398.
21. Zhu, X., Walton, R. G., Tian, L., Luo, N. et al., Prostaglandin A2 enhances cellular insulin sensitivity via a mechanism that involves the orphan nuclear receptor NR4A3. Horm. Metab. Res. 2013, 45, 213-220.
22. Giles, H., Leff, P., The biology and pharmacology of PGD2. Prostaglandins 1988, 35, 277-300. Review.
23. Kikuchi, Y., Kita, T., Hirata, J., Kuki, E. et al., Modulation of human lymphocyte response to phytohemagglutinin by antineoplastic prostaglandins. Int. J. Immunopharmacol. 1992, 14, 105-110.
24. Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I. et al., A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 1995, 83, 813-819.
25. Tai, H. H., Cho, H., Tong, M., Ding, Y., NAD+-linked 15-hydroxyprostaglandin dehydrogenase: structure and biological functions. Curr. Pharm. Des. 2006, 12, 955-962.
26. Hansen, H. S., Purification and characterization of a 15-ketoprostaglandin delta 13-reductase from bovine lung. Biochim. Biophys. Acta 1979, 574, 136-145.
27. Diczfalusy, U., Alexson, S. E., Identification of metabolites from peroxisomal beta-oxidation of prostaglandins. J. Lipid Res. 1990, 31, 307-314.
28. Hemler, M. E., Lands, W. E., Evidence for a peroxide-initiated free radical mechanism of prostaglandin biosynthesis. J. Biol. Chem. 1980, 255, 6253-6261.
29. Hamberg, M., Svensson, J., Samuelsson, B., Prostaglandin endoperoxides. A new concept concerning the mode of action and release of prostaglandins. Proc. Natl. Acad. Sci. U.S.A. 1974, 71, 3824-3828.
30. Hecker, M., Haurand, M., Ullrich, V., Diczfalusy, U., Hammarström, S., Products, kinetics, and substrate specificity of homogeneous thromboxane synthase from human platelets: development of a novel enzyme assay. Arch. Biochem. Biophys. 1987, 254, 124-135.
31. Hamberg, M., Svensson, J., Samuelsson, B., Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci. USA 1975, 72, 2994-2998.
32. Whittaker, N., Bunting, S., Salmon, J., Moncada, S. et al., The chemical structure of prostaglandin X (prostacyclin). Prostaglandins 1976, 12, 915-928.
33. Ursini, F., Bindoli, A., The role of selenium peroxidases in the protection against oxidative damage of membranes. Chem. Phys. Lipids 1987, 44, 255-276.
34. Bacot, S., Bernoud-Hubac, N., Baddas, N., Chantegrel, B. et al., Covalent binding of hydroxy-alkenals 4-HDDE, 4-HHE, and 4-HNE to ethanolamine phospholipid subclasses. J. Lipid Res. 2003, 44, 917-926.
35. Coulon, L., Calzada, C., Moulin, P., Véricel, E., Lagarde, M., Activation of p38 mitogen-activated protein kinase/cytosolic phospholipase A2 cascade in hydroperoxide-stressed platelets. Free Radic. Biol. Med. 2003, 35, 616-625.
36. Siegel, M. I., McConnell, R. T., Abrahams, S. L., Porter, N. A., Cuatrecasas, P., Regulation of arachidonate metabolism via lipoxygenase and cyclo-oxygenase by 12-HPETE, the product of human platelet lipoxygenase. Biochem. Biophys. Res. Commun. 1979, 89, 1273-1280.
37. Hemler, M. E., Cook, H.W., Lands, W.E., Prostaglandin biosynthesis can be triggered by lipid peroxides. Arch. Biochem. Biophys. 1979, 193, 340-345.
38. Calzada, C., Vericel, E., Lagarde, M., Low concentrations of lipid hydroperoxides prime human platelet aggregation specifically via cyclo-oxygenase activation. Biochem. J. 1997, 325, 495-500.
39. Solomon, E. I., Zhou, J., Neese, F., Pavel, E. G., New insights from spectroscopy into the structure/function relationships of lipoxygenases. Chem. Biol. 1997, 4, 795-808.
40. Samuelsson, B., Funk, C. D., Enzymes involved in the biosynthesis of leukotriene B4. J. Biol. Chem. 1989, 264, 19469-19472.
41. Bray, M. A., Leukotriene B4: an inflammatory mediator with vascular actions in vivo. Agents Actions Suppl. 1982, 11, 51-61.
42. Hammarström, S., Leukotrienes. Annu. Rev. Biochem. 1983, 52, 355-377.
43. Piper, P. J., Pharmacology of leukotrienes. Br. Med. Bull. 1983, 39, 255-259.
44. Harder, D. R., Campbell, W. B., Roman, R. J., Role of cytochrome P-450 enzymes and metabolites of arachidonic acid in the control of vascular tone. J. Vasc. Res. 1995, 32, 79-92.
45. Spector, A. A., Fang, X., Snyder, G. D., Weintraub, N. L., Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog. Lipid Res. 2004, 43, 55-90.
46. Pace-Asciak, C. R., Hepoxilins: a review on their cellular actions. Biochim. Biophys. Acta 1994, 1215, 1-8.
47. Salomon, R. G., Distinguishing levuglandins produced through the cyclooxygenase and isoprostane pathways. Chem. Phys. Lipids 2005, 134, 1-20.
48. Serhan, C. N., Samuelsson, B., Lipoxins: a new series of eicosanoids (biosynthesis, stereochemistry, and biological activities). Adv. Exp. Med. Biol. 1988, 229, 1-14.
49. Feltenmark, S., Gautam, N., Brunnström, A., Griffiths, W. et al., Eoxins are proinflammatory arachidonic acid metabolites produced via the 15-lipoxygenase-1 pathway in human eosinophils and mast cells. Proc. Natl. Acad. Sci. USA 2008, 105, 680-685.
50. Gupta, S., Maurya, M. R., Stephens, D. L., Dennis, E. A., Subramaniam, S., An integrated model of eicosanoid metabolism and signaling based on lipidomics flux analysis. Biophys. J. 2009, 96, 4542-4551.
51. Norris, P. C., Dennis, E. A., Omega-3 fatty acids cause dramatic changes in TLR4 and purinergic eicosanoid signaling. Proc. Natl. Acad. Sci. USA 2012, 109, 8517-8522.
52. Leaf, A., Weber, P. C., Cardiovascular effects of n-3 fatty acids. N. Engl. J. Med. 1988, 318, 549-557.
53. Needleman, P., Sprecher, H., Whitaker, M. O., Wyche, A., Mechanism underlying the inhibition of platelet aggregation by eicosapentaenoic acid and its metabolites. Adv. Prostaglandin Thromboxane Res. 1980, 6, 61-68.
54. Boukhchache, D., Lagarde, M., Interactions between prostaglandin precursors during their oxygenation by human platelets. Biochim. Biophys. Acta 1982, 713, 386-392.
55. Lagarde, M., Drouot, B., Guichardant, M., Dechavanne, M., In vitro incorporation and metabolism of some icosaenoic acids in platelets. Effect on arachidonic acid oxygenation. Biochim. Biophys. Acta 1985, 833, 52-58.
56. Needleman, P., Minkes, M., Raz, A., Thromboxanes: selective biosynthesis and distinct biological properties. Science 1976, 193, 163-165.
57. Moncada, S., Vane, J. R., The role of prostacyclin in vascular tissue. Fed. Proc. 1979, 38, 66-71.
58. Calder, P. C., Polyunsaturated fatty acids and inflammatory processes: new twists in an old tale. Biochimie 2009, 91, 791-795.
59. Tull, S. P., Yates, C. M., Maskrey, B. H., O'Donnell, V. B. et al., Omega-3 Fatty acids and inflammation: novel interactions reveal a new step in neutrophil recruitment. PLoS Biol. 2009, 7, e1000177.
60. Whitaker, M. O., Wyche, A., Fitzpatrick, F., Sprecher, H., Needleman, P., Triene prostaglandins: prostaglandin D3 and icosapentaenoic acid as potential antithrombotic substances. Proc. Natl. Acad. Sci. U.S.A. 1979, 76, 5919-5923.
61. Tjonahen, E., Oh, S. F., Siegelman, J., Elangovan, S. et al., Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Chem. Biol. 2006, 13, 1193-1202.
62. Isobe, Y., Arita, M., Matsueda, S., Iwamoto, R. et al., Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17, 18-dihydroxyeico-sapentaenoic acid. J. Biol. Chem. 2012, 287, 10525-10534.
63. Lefils-Lacourtablaise, J., Socorro, M., Géloën, A., Daira, P. et al., 15-Deoxy-D12, 14-prostaglandin J3: a novel eicosapentaenoic acid-derived prostaglandin that increases adiponectin secretion by adipocytes partly via a PPARg-dependent mechanism, submitted (revision). PLoS One 2013, 29, e63997.
64. Rao, G. H., Radha, E., White, J. G., Effect of docosahexaenoic acid (DHA) on arachidonic acid metabolism and platelet function. Biochem. Biophys. Res. Commun. 1983, 117, 549-555.
65. Aveldaño, M. I., Sprecher, H., Synthesis of hydroxy fatty acids from 4, 7, 10, 13, 16, 19-[1-14C] docosahexaenoic acid by human platelets. J. Biol. Chem. 1983, 258, 9339-9343.
66. Ariel, A., Li, P. L., Wang, W., Tang, W. X. et al., The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering. J. Biol. Chem. 2005, 280, 43079-43086.
67. Mukherjee, P. K., Marcheselli, V. L., Serhan, C. N., Bazan, N.G., Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc. Natl. Acad. Sci. USA 2004, 101, 8491-8496.
68. Chen, P., Fenet, B., Michaud, S., Tomczyk, N. et al., Full characterization of PDX, a neuroprotectin/protectin D1 isomer, which inhibits blood platelet aggregation. FEBS Lett. 2009, 583, 3478-3484.
69. Serhan, C. N., Yang, R., Martinod, K., Kasuga, K. et al., Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J. Exp. Med. 2009, 206, 15-23.
70. Clària, J., Dalli, J., Yacoubian, S., Gao, F., Serhan, C. N., Resolvin D1 and resolvin D2 govern local inflammatory tone in obese fat. J. Immunol. 2012, 189, 2597-2605.
71. Chen, P., Véricel, E., Lagarde, M., Guichardant, M., Poxytrins, a class of oxygenated products from polyunsaturated fatty acids, potently inhibit blood platelet aggregation. FASEB J. 2011, 25, 382-388.
72. Yamamoto, K., Itoh, T., Abe, D., Shimizu, M. et al., Identification of putative metabolites of docosahexaenoic acid as potent PPARgamma agonists and antidiabetic agents. Bioorg. Med. Chem. Lett. 2005, 15, 517-522.
73. Lagarde, M., Gharib, A., Dechavanne, M., Different utilization of arachidonic and dihomogammalinolenic acids by human platelet prostaglandin synthetase. Biochimie 1977, 59, 935-937.
74. Colman, R. W., Figures, W. R., Characteristics of an ADP receptor mediating platelet activation. Mol. Cell. Biochem. 1984, 59, 101-111.
75. Di Minno, G., Silver, M. J., de Gaetano, G., Prostaglandins as inhibitors of human platelet aggregation. Br. J. Haematol. 1979, 43, 637-647.
76. Tobias, L. D., Vane, F. M., Paulsrud, J. R., The biosynthesis of 1a, 1b-dihomo-PGF2 and 1a, 1b-dihomo-PGF2 alpha from 7, 10, 13, 16-docosatetraenoic acid by an acetone-pentane powder of sheep vesicular gland microsomes. Prostaglandins 1975, 10, 443-468.
77. Milks, M. M., Sprecher, H., Metabolism of 4, 7, 10, 13, 16-docosapentaenoic acid by human platelet cyclooxygenase and lipoxygenase. Biochim. Biophys. Acta 1985, 835, 29-35.
78. Homayoun, P., Durand, G., Pascal, G., Bourre, J. M., Alteration in fatty acid composition of adult rat brain capillaries and choroid plexus induced by a diet deficient in n-3 fatty acids: slow recovery after substitution with a non-deficient diet. J. Neurochem. 1988, 51, 45-48.
79. Dangi, B., Obeng, M., Nauroth, J. M., Teymourlouei, M. et al., Biogenic synthesis, purification, and chemical characterization of anti-inflammatory resolvins derived from docosapentaenoic acid (DPAn-6). J. Biol. Chem. 2009, 284, 14744-14759.
80. Guichardant, M., Lagarde, M., Studies on platelet lipoxygenase specificity towards icosapolyenoic and docosapolyenoic acids. Biochim. Biophys. Acta 1985, 836, 210-214.
81. Lundberg, W. O., The significance of cis, cis, cis 5, 8, 11 eicosatrienoic acid in essential fatty acid deficiency. Nut. Rev. 1980, 38, 233-235.
82. Jakschik, B. A., Morrison, A. R., Sprecher, H., Products derived from 5, 8, 11-eicosatrienoic acid by the 5-lipoxygenase-leukotriene pathway. J. Biol. Chem. 1983, 258, 12797-12800.
83. Hammarström, S., Conversion of 5, 8, 11-eicosatrienoic acid to leukotrienes C3 and D3. J. Biol. Chem. 1981, 256, 2275-2279.
84. Lagarde, M., Burtin, M., Rigaud, M., Sprecher, H. et al., Prostaglandin E2-like activity of 20:3n-9 platelet lipoxygenase end-product. FEBS Lett. 1985, 181, 53-56.
85. Hamberg, M., Steric analysis of hydroperoxides formed by lipoxygenase oxygenation of linoleic acid. Anal. Biochem. 1971, 43, 515-526.
86. Buchanan, M. R., Haas, T. A., Lagarde, M., Guichardant, M., 13-Hydroxyoctadecadienoic acid is the vessel wall chemorepellant factor, LOX. J. Biol. Chem. 1985, 260, 16056-16059.
87. Kaduce, T. L., Figard, P. H., Leifur, R., Spector, A. A., Formation of 9-hydroxyoctadecadienoic acid from linoleic acid in endothelial cells. J. Biol. Chem. 1989, 264, 6823-6830.
88. Liu, M., Chen, P., Véricel, E., Lelli, M. et al., Characterization and biological effects of di-hydroxylated compounds deriving from the lipoxygenation of alpha-linolenic acid. J. Lipid Res. 2013, doi: 10.1194/jlr.M035139.
89. Liu, M., Boussetta, T., Makni, K., Driss, F. et al., Protectin DX, a double lipoxygease product of DHA, inhibits ROS production in human neutrophils, and cyclooxygenase activities. Submitted.
90. Laneuville, O., Breuer, D. K., Xu, N., Huang, Z. H. et al., Fatty acid substrate specificities of human prostaglandin-endoperoxide H synthase-1 and -2. Formation of 12-hydroxy-(9Z, 13E/Z, 15Z)- octadecatrienoic acids from alpha-linolenic acid. J. Biol. Chem. 1995, 270, 19330-19336.
91. Kühn, H., Belkner, J., Wiesner, R., Alder, L., Occurrence of 9- and 13-keto-octadecadienoic acid in biological membranes oxygenated by the reticulocyte lipoxygenase. Arch. Biochem. Biophys. 1990, 279, 218-224.
92. Fruteau de Laclos, B., Borgeat, P., Conditions for the formation of the oxo derivatives of arachidonic acid from platelet 12-lipoxygenase and soybean 15-lipoxygenase. Biochim. Biophys. Acta 1988, 958, 424-433.
93. Patel, P., Cossette, C., Anumolu, J. R., Gravel, S. et al., Structural requirements for activation of the 5-oxo-6E, 8Z, 11Z, 14Z-eicosatetraenoic acid (5-oxo-ETE) receptor: identification of a mead acid metabolite with potent agonist activity. J. Pharmacol. Exp. Ther. 2008, 325, 698-707.
94. Schneider, C., Brash, A. R., Lipoxygenase-catalyzed formation of R-configuration hydroperoxides. Prostagland. Other Lipid Mediat. 2002, 68-69, 291-301.
95. Guichardant, M., Bacot, S., Molière, P., Lagarde, M., Hydroxy-alkenals from the peroxidation of n-3 and n-6 fatty acids and urinary metabolites. Prostaglandins Leukot. Essent. Fatty Acids 2006, 75, 179-182.
96. Catalá, A., Lipid peroxidation of membrane phospholipids generates hydroxy-alkenals and oxidized phospholipids active in physiological and/or pathological conditions. Chem. Phys. Lipids 2009, 157, 1-11.
97. Amunom, I., Stephens, L. J, Tamasi, V., Cai, J. et al., Cytochromes P450 catalyze oxidation of alpha, beta-unsaturated aldehydes. Arch. Biochem. Biophys. 2007, 464, 187-196.
98. Roberts, L. J., 2nd, Morrow, J. D., Isoprostanes. Novel markers of endogenous lipid peroxidation and potential mediators of oxidant injury. Ann. N. Y. Acad. Sci. 1994, 744, 237-242.
99. VanRollins, M., Woltjer, R. L., Yin, H., Morrow, J. D., Montine, T. J., F2-dihomo-isoprostanes arise from free radical attack on adrenic acid. J. Lipid Res. 2008, 49, 995-1005.
100. Montine, K. S., Quinn, J. F., Zhang, J., Fessel, J. P. et al., Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem. Phys. Lipids 2004, 128, 117-124.
101. Durand, T., Bultel-Poncé, V., Guy, A., Berger, S. et al., New bioactive oxylipins formed by non-enzymatic free-radical-catalyzed pathways: the phytoprostanes. Lipids 2009, 44, 875-888.
102. Basu, S., Isoprostanes: novel bioactive products of lipid peroxidation. Free Radic. Res. 2004, 38, 105-122.
103. Davies, S. S., Amarnath, V., Roberts, L. J., 2nd, Isoketals: highly reactive gamma-ketoaldehydes formed from the H2-isoprostane pathway. Chem. Phys. Lipids 2004, 128, 85-99.
104. Bernoud-Hubac, N., Roberts, L. J., 2nd, Identification of oxidized derivatives of neuroketals. Biochemistry 2002, 41, 11466-11471.
105. Brame, C. J., Boutaud, O., Davies, S. S., Yang, T. et al., Modification of proteins by isoketal-containing oxidized phospholipids. J. Biol. Chem. 2004, 279, 13447-13451.
106. Bernoud-Hubac, N., Davies, S. S., Boutaud, O., Montine, T. J., Roberts, L. J., 2nd, Formation of highly reactive gamma-ketoaldehydes (neuroketals) as products of the neuroprostane pathway. J. Biol. Chem. 2001, 276, 30964-30970.
107. Bernoud-Hubac, N., Fay, L. B., Armarnath, V., Guichardant, M. et al., Covalent binding of isoketals to ethanolamine phospholipids. Free Radic. Biol. Med. 2004, 37, 1604-1611.
108. Mechoulam, R., Fride, E., Di Marzo, V., Endocannabinoids. Eur. J. Pharmacol. 1998, 359, 1-18.
109. Woodward, D. F., Liang, Y., Krauss, A. H., Prostamides (prostaglandin-ethanolamides) and their pharmacology. Br. J. Pharmacol. 2008, 153, 410-419.
110. Rouzer, C. A., Marnett, L. J., Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. Chem. Rev. 2011, 111, 5899-5921.
111. Bisogno, T., Delton-Vandenbroucke, I., Milone, A., Lagarde, M., Di Marzo, V., Biosynthesis and inactivation of N-arachidonoylethanolamine (anandamide) and N-docosahexaenoylethanolamine in bovine retina. Arch. Biochem. Biophys. 1999, 370, 300-307.
112. Kim, H. Y., Spector, A. A., Xiong, Z. M., A synaptogenic amide N-docosahexaenoylethanolamide promotes hippocampal development. Prostagland. Other Lipid Mediat. 2011, 96, 114-120.
113. Lagarde, M., Géloën, A., Record, M., Vance, D., Spener, F., Lipidomics is emerging. Biochim. Biophys. Acta 2003, 1634, 61.
114. Lagarde, M., Bernoud-Hubac, N., Guichardant, M., Expanding the horizons of lipidomics. Towards fluxolipidomics. Mol. Membr. Biol. 2012, 29, 222-228.
115. Brossard, N., Pachiaudi, C., Croset, M., Normand, S. et al., Stable isotope tracer and gas-chromatography combustion isotope ratio mass spectrometry to study the in vivo compartmental metabolism of docosahexaenoic acid. Anal. Biochem. 1994, 220, 192-199.